These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

822 related items for PubMed ID: 16573364

  • 1. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP.
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J.
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [Abstract] [Full Text] [Related]

  • 4. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D.
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Vaccination against human papillomavirus for the prevention of cervical cancer].
    Quint WG, ter Harmsel WA, van Doorn LJ.
    Ned Tijdschr Geneeskd; 2006 Jun 24; 150(25):1380-4. PubMed ID: 16841585
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S, Alain S, Denis F.
    Gynecol Obstet Fertil; 2006 Jun 24; 34(7-8):647-55. PubMed ID: 16807045
    [Abstract] [Full Text] [Related]

  • 11. [Can human papillomavirus testing and vaccination prevent cervical cancer?].
    Lie AK, Bjørge T, Helland A, Hagen B, Skjeldestad FE, Hagmar B, Thoresen S.
    Tidsskr Nor Laegeforen; 2001 Oct 20; 121(25):2947-51. PubMed ID: 11715778
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
    Kohl I.
    Klin Mikrobiol Infekc Lek; 2006 Jun 20; 12(3):91-7. PubMed ID: 17051469
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of preventive human papillomavirus vaccination.
    Lehtinen M, Paavonen J.
    Int J STD AIDS; 2003 Dec 20; 14(12):787-92. PubMed ID: 14678583
    [Abstract] [Full Text] [Related]

  • 17. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF.
    Adv Ther; 2009 Nov 20; 26(11):983-98. PubMed ID: 20024678
    [Abstract] [Full Text] [Related]

  • 18. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [Abstract] [Full Text] [Related]

  • 19. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
    Syrjänen KJ.
    Scand J Infect Dis Suppl; 2009 Aug 19; 107():3-32. PubMed ID: 19408160
    [Abstract] [Full Text] [Related]

  • 20. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.